Ethics statement

Data included in this analysis were obtained in accordance with ethical approvals from the location of origin. Data were requested to be shared anonymized. A non-human subjects use protocol was established for the acquisition of IPD, reviewed by the Walter Reed Army Institute of Research (WRAIR#2458). Consent was not obtained because data were analyzed anonymously.

Literature review

Reports on the use of ivermectin in children weighing less than 15 kg were searched for on the following databases: MEDLINE via PubMed, Web of Science, Ovid Embase, LILACS, Cochrane Database of Systematic Reviews, TOXLINE, and ClinicalTrials.gov. Databases were searched in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses of individual participant data (PRISMA) statement (S1 Checklist) [20]. Clinical trials, case series, case reports, and database entries published between 1 January 1980 to 25 October 2019 in any language describing ivermectin use in small children were identified. The US Food and Drug Administration, the Australian Adverse Drug Reactions Advisory Committee, the EudraVigilance system, and Vigibase (maintained by the WHO Collaborating Centre for International Drug Monitoring) were contacted for case reports of ivermectin adverse reactions in children weighing less than 15 kg however, these databases do not collect weights of individuals so no data could be contributed to this study. The protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO): CRD42017056515. Three independent investigators undertook the review process and extracted the data (PJ, WM, KCK), resolving discrepancy through discussion. Search terms included but were not restricted to: (soolantra OR sklice OR oramec OR mk933 OR "mk 933" OR ivomec OR eqvalan OR eqvalen OR epimer OR diapec OR cardomec OR stromectol OR mectizan OR ivermectin) AND (child or children OR newborn* OR infan* or new-born* or perinat* or neonat* or baby* or babies or toddler* or boy or boys or girl or girls or kid or kids or pediatric* or paediatric* or peadiatric* or prematur* or preterm* OR "low birth weight" or vlbw or lbw or preschool*). Screening was based on the title and abstract, and if treatment based on age (≤5 years old) or weight (<15 kg) was not clearly defined, then a review of the manuscript was performed. To confirm if ivermectin was used in children weighing less than 15 kg, authors of possible reports of ivermectin use in small children were contacted via email on at least 3 attempts in English, and when warranted in French, Portuguese, Spanish, or Swedish. In some cases, attempts were made to call and/or message authors via ResearchGate.

Lead investigators of identified studies were contacted to share individual-level patient data IPD. Only studies including weight of ivermectin-treated children less than 15 kg and adverse events data were considered for the final IPD meta-analysis. Adverse events were defined as the appearance or worsening of any undesirable sign, symptom, or medical condition after starting the study drug, even if the event was not considered related to the study drug. Serious Adverse Events (SAEs) were defined as any untoward medical occurrence that at any dose: resulted in death; was life-threatening; required inpatient hospitalization or resulted in prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; or was a medically important event or reaction [21].

Additional patient-level data including disease indication for ivermectin use, manufacturer, brand name, dose, regimen, and delivery method were requested. IPD shared with the WorldWide Antimalarial Resistance Network (WWARN) were curated and standardized as described in a data management plan [22]. Any data inconsistencies or missing information were resolved directly with the investigators. Descriptive summaries were made to describe the risk of selection bias and reporting bias from the IPD contributing studies.

Outcome

The primary outcome was the incidence of adverse events in children weighing less than 15 kg that ingested oral ivermectin.

Statistical analysis

Since data were limited and heterogenous, mostly descriptive analyses were conducted. Incidences of AEs, their grading and causality classification, as determined by the on-site principal investigator or physician in each study were pooled and analyzed. Incidence of any AEs in children weighing less than 15 kg who were treated for scabies was estimated by pooling data from cohort, MDA or randomized studies (excluding case reports/series) using fixed logistic regression model (stata command metapreg). Heterogeneity between studies was quantified using I² measure. Exact confidence intervals are presented for individual studies and for rate of SAE. Risk of bias was assessed based on study design and AE elicitation method.

Systematic review summary

A total of 3,730 potential publications were identified and assessed for eligibility from literature database searches, of which 97 were selected for potential inclusion in the review (Fig 1). We attempted to contact all authors of the publications, and received responses for only 59.8% (58/97) of publications. Of responding authors, 29.3% (17/58) successfully provided IPD on ivermectin use in children weighing less than 15 kg, while 31.0% (18/58) confirmed that oral ivermectin was not provided to children weighing less than 15 kg, 8.6% (5/58) reported they no longer had access to the data, 6.9% (4/58) reported that ivermectin was used in children weighing less than 15 kg but weight or adverse event data were not recorded or were not available, 22.4% (13/58) reported they used ivermectin in children weighing less than 15 kg but failed to provide the IPD data, and 1.7% (1/58) reported that children weighing less than 15 kg will be treated with oral ivermectin but the study has not started yet (S1 Table). Overall, 17 reports describing 15 studies provided IPD. Characteristics of the 15 included studies are summarized in Table 1. Study designs utilized include: case reports 46.7% (7/15; 10 subjects), case series 26.7% (4/15; 175 subjects), cohort studies 6.7% (1/15; 4 subjects), MDA 6.7% (1/15; 838 subjects), a prospective observational study 6.7% (1/15; 17 subjects), and a randomized controlled trial 6.7% (1/15; 44 subjects). No issues were identified in IPD integrity.

Download:

• PPT
  PowerPoint slide
• PNG
  larger image
• TIFF
  original image

Fig 1. PRISMA IPD flow diagram.

Fig 1 depicts the total number of studies identified from systematic review, rationale for exclusion, and number of studies included in the final analyses. * See S1 Table for list of studies and rationale for inclusion or exclusion from the review.

https://doi.org/10.1371/journal.pntd.0009144.g001

Download:

• PPT
  PowerPoint slide
• PNG
  larger image
• TIFF
  original image

Table 1. Study characteristics.

https://doi.org/10.1371/journal.pntd.0009144.t001

IPD summary

From the 17 reports, there were 1,088 confirmed instances in which oral ivermectin was given to children weighing less than 15 kg. The majority of the treated children (80.2%, 867/1,081) were younger than five years of age with an overall median age of 36 months (range 1–132 months). Median weight was 13.0 kg (range 4.0–14.9 kg). Height was only available in 5 out of 15 studies, for 10.9% (119/1,088) of children, with a median of 84 cm (range 54–103 cm) and 28.6% (34/119) were 90 cm or taller.

Of ivermectin-treated children, 82.8% (901/1,088) received two doses of ivermectin anywhere from 1 to 19 days apart. Although 200 μg/kg of ivermectin is the standard oral dose for most NTDs, 86.5% (941/1,088) children received a dose between 201–300 μg/kg and 1.7% (19/1,088) received doses above 300 μg/kg (Fig 2). Overall, the median dose administered was 221 μg/kg (range 81–556 μg/kg). The doses administered were significantly higher in the two-dose regimen (median 231 μg/kg, range 94–556, n = 901) compared to the single-dose regimen (median 214 μg/kg, range 81–500 μg/kg, n = 187), (p<0.001, Mann Whitney test).

Download:

• PPT
  PowerPoint slide
• PNG
  larger image
• TIFF
  original image

Fig 2. Ivermectin dose and number administered to children weighing less than 15 kg.

Fig 2 depicts the ivermectin dose administered in μg/kg (inner ring) and the number of doses administered (outer ring) that were collected for the IPD database (n = 1,088).

https://doi.org/10.1371/journal.pntd.0009144.g002

Oral ivermectin was administered to children weighing less than 15 kg for a total of nine indications including: scabies MDA 77.0% (838/1,088), scabies individual treatment 17.3% (188/1,088), trichuriasis 4.0% (44/1,088), strongyloidiasis 0.8% (9/1,088), cutaneous larva migrans 0.4% (4/1,088), crusted scabies 0.2% (2/1,088), myiasis 0.1% (1/1,088), pthiriasis 0.1% (1/1,088), and parasitic disease of unknown origin 0.1% (1/1,088). Instances of ivermectin administration to children weighing less than 15 kg were reported from ten countries including: Solomon Islands 77.0% (838/1,088), France 17.4% (189/1,088), Côte d’Ivoire 4.0% (44/1,088), Mexico 0.5% (5/1,088), Cambodia 0.4% (4/1,088), Spain 0.4% (4/1,088), Brazil 0.1% (1/1,088), Guadeloupe 0.1% (1/1,088), Peru 0.1% (1/1,088), and Venezuela 0.1% (1/1,088).

In total, 18 AEs were reported from 1.4% (15/1,088) of ivermectin-treated children and none of the AEs (0/18, 95%CI 0–0.33%) were deemed SAEs (Table 2). The most common AEs reported were diarrhea 0.4% (4/1,088) and eczema 0.5% (5/1,088). Headache, itching and vomiting were each reported twice 0.2% (2/1,088) and joint pain, abdominal pain, and symmetrical edema of the feet were each reported once 0.1% (1/1,088) (Tables 2 and S2). Twelve patients reported only one AE, while three patients reported 2 AEs: headache and diarrhea (n = 1), abdominal pain and vomiting (n = 1), diarrhea and itching (n = 1). All AEs were deemed possibly related to ivermectin administration, except for the joint pain which was classified as unlikely related to ivermectin administration. Adverse events were related to scabies treatment or MDA for scabies in 50% (9/18), trichuriasis in 44.4% (8/18), and strongyloidiasis in 5.6% (1/18) of patients. A pooled prevalence of AEs in the scabies, crusted scabies, or scabies MDA data derived from 3 studies, was estimated as 0.88% (95%CI 0.48–1.68) (Table 3). Seven of the AEs occurred in children that were co-administered either topical creams for scabies (4/7), oral azithromycin (2/7), or intravenous iron plus vitamin supplements (1/7) (Table 2). No adverse events were reported in the 1.3% (14/1,081) of children three months or younger. Of 128 children who received ≤200 μg/kg ivermectin, 7.0% (9/128) experienced an AE, of 960 children who received >200 μg/kg ivermectin 0.6% (6/960) reported an AE, and of 19 children who received >300 μg/kg ivermectin none reported an AE. All AEs were considered mild, self-limiting, and resolved without further intervention.

Download:

• PPT
  PowerPoint slide
• PNG
  larger image
• TIFF
  original image

Table 2. Listing of individual adverse events (n = 18) following ivermectin ingestion.

None of the AEs were classified as serious adverse events.

https://doi.org/10.1371/journal.pntd.0009144.t002

Download:

• PPT
  PowerPoint slide
• PNG
  larger image
• TIFF
  original image

Table 3. Pooled AE incidence in children with Scabies, Crusted scabies, or participating in MDAs for scabies (excluding case studies) from a fixed effects logistic regression model.

I² statistics (variation in log-odds attributable to heterogeneity) = 21.4%.

https://doi.org/10.1371/journal.pntd.0009144.t003

Risk of bias

A single patient case report or small case series does not allow for estimation of AE frequency, but provides descriptive or narrative results. Therefore, case reports or case series in our review (study IDs 2–11,17) [8,23–32] with patients (n = 16) seen in the clinic were categorized as high risk of selection and reporting bias.

Among the remaining studies, low risk of selection bias is expected in the randomized control study (study ID 14) [33] (n = 44) and the MDA trial (study ID 13) [34] in which all eligible persons in the study area were treated (n = 838) and participants from randomly selected villages were followed up for AEs, and moderate risk in the prospective studies (study IDs 1,15,16) [35–37] (n = 21). Only two studies actively asked for AEs (study ID 12,14) [9,33] (n = 213), while MDA (study ID 13) [34] (n = 838) and cohort studies (study ID 15,16) [35,36] (n = 4) used passive reporting of AEs, and were categorized a high risk for reporting bias.

One study identified by the review [10] could not be included in the analysis because AEs were not linked to individual patients. The article reported that among 15 children weighing<15kg treated for scabies, two experienced AEs (one was nervous and irritable and the other scratched intensely). Including this study would slightly increase the pooled AE frequency to 1.06% (95% CI 0.59–1.90%) (Table 3). In any other studies (n = 79) for which IPD could not be obtained, data published could not be used in the synthesis as the AEs and number of patients studied were not presented explicitly in the weight group of interest. Consequently, we cannot assess representativeness of the IPD collated in relation to all ivermectin use data available in this weight group.

Ivermectin treatment and mass drug administration for scabies

Several trials of ivermectin MDA for the control of scabies have been performed in the South Pacific [34,40,41]. Adequate population coverage is critical for the success of scabies MDA. The use of oral ivermectin has logistical and compliance advantages over topical creams. Furthermore, MDA of oral ivermectin was found to be more effective than topical permethrin [40]. Children not treated by ivermectin during MDA serve as a reservoir for future community re-infection unless adequately treated with topical treatments. One MDA trial for scabies in the Solomon Islands co-administered ivermectin and azithromycin for the control of scabies and impetigo. Azithromycin is indicated for use in children weighing 12.5 kg or more, and in the trial in the Solomon Islands the 12.5 kg limit was also used for ivermectin for pragmatic reasons. A total of 838 children weighing 12.5 to less than 15 kg received ivermectin as part of MDA, and only two adverse events were reported in this group [34].

In 2018, Ethiopia performed the largest scabies ivermectin MDA to date, treating 1,634,271 persons with oral ivermectin. Drug administration was not based on height or weight but by age. Children two to six years old were administered a single 3 mg ivermectin tablet, with 147,380 children in this age range treated [42]. Based on WHO Child Growth Standards, the median weight for a 24-month-old child is 12.2 kg for boys and 11.5 kg for girls, with children achieving a median 15.0 kg weight at 40 months for boys and at 42 months for girls [6]. Enbiale et al. report that roughly 30% of children aged two to six years old were given more costly and logistically difficult to administer topical permethrin or sulfur creams instead of oral ivermectin, which may have occurred because of confusion with onchocerciasis guidelines indicating that children under five years of age should not be treated with ivermectin [42]. In this review, of the children weighing less than 15 kg treated with oral ivermectin, 19.8% (214/1,081) were five years of age or older. While this data set is limited, it suggests that treating by age with five years old as a cutoff would still frequently provide ivermectin to children weighing less than 15 kg. Of the children weighing less than 15 kg treated with oral ivermectin, 28.6% (34/119) were 90 cm or taller. This illustrates that the 90 cm cutoff for ivermectin administration during MDAs means that children weighing less than 15 kg are routinely treated with ivermectin. Establishing the safety of ivermectin in children weighing less than 15 kg would remove the imprecise weight, height, and age restriction barriers and facilitate more streamlined ivermectin MDAs.

Scabies is recognized in France as a common clinical problem, including in small children. In 2014, the French Medicines Regulatory Agency “Agence Nationale de Sécurité du Médicament”, published a decision algorithm for treatment of scabies in children aged less than one year. This algorithm recommends treatment with two doses of oral ivermectin (200 μg/kg) one week apart in infants who fail scabies treatment with permethrin or benzyl benzoate topical creams, or have a contraindication for topical esdepallethrin spray (e.g. asthma) [43]. A survey of French dermatologists found that oral ivermectin was unlikely to be used in infants with common scabies weighing less than 10 kg (15%). However, willingness to use oral ivermectin in children weighing less than 10 kg increased: if the child had asthma (25%), after topical cream failure (40%), complications with impetigo (60%), profuse scabies (70%), or if the child was unlikely to be seen again follow-up (65%). Furthermore, survey respondents were willing to treat scabies in children less than three months with oral ivermectin [44]. Indeed, in this current review, of the 14 children that were three months or younger that were administered oral ivermectin, all of them were treated for scabies and 92.9% (13/14) were treated in France. France appears to be the first country with clear guidance to use oral ivermectin off-label for treatment of scabies in children weighing less than 15 kg.

Ivermectin treatment for soil-transmitted helminthiasis and strongyloidiasis

Ivermectin has been used for the treatment of young children weighing less than 15 kg with infections due to STHs or Strongyloides stercoralis. The combination of ivermectin and albendazole is superior to either drug alone for the treatment of Trichuris trichiura [45] and albendazole is superior to ivermectin for the treatment of hookworm. The Global Program for the Elimination of Lymphatic Filariasis (GPELF) co-administered ivermectin and albendazole to 52 million school-aged children via MDA in 2015 [46] and this combination has been added to the WHO List of Essential Medicines for Children [47]. However, the combination is still not used in children weighing less than 15 kg because of the ivermectin contraindication. Part of the GPELF rationale for albendazole and ivermectin co-administration was increased secondary effects against STHs [48]. The triple-drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA) was recently shown to be superior for the treatment of lymphatic filariasis [49] and Merck has pledged an additional 100 million ivermectin treatments annually to use in triple-drug therapy IDA MDAs outside of Africa [50]. However, with the success of the GPELF against lymphatic filariasis, MDA is now scaling back in many areas. If community-wide MDA programs with ivermectin and albendazole are to continue in the future, then STH programs will have to shift strategies from school-based administration of albendazole to community-wide MDAs with combinations of ivermectin and albendazole, and inclusion of children weighing less than 15 kilograms could be considered.

A recent clinical trial demonstrated that ivermectin for T. trichiura infection is safe in preschool-aged children, some of whom weighed less than 15 kg (n = 44) [33], but safety studies of the combination of ivermectin and albendazole in children weighing less than 15 kg are lacking. STH infection at a young age is associated with growth stunting, impairment of cognitive development, and reduced school attendance. Co-administration of ivermectin and albendazole during MDAs to small children infected with STHs could positively impact childhood development in many settings.

Expanding ivermectin use for children weighing less than 15 kg during MDAs could have marked health benefits for this group through impact on S. stercoralis burden. Repeated annual ivermectin MDA for onchocerciasis control in Colombia [51] and Ecuador [52] demonstrated marked and sustained reductions in S. stercoralis prevalence. Three rounds of annual ivermectin and albendazole MDA in Argentina [53] and two rounds of annual ivermectin MDA in Australia [54] led to marked reduction on S. stercoralis prevalence. Strongyloidiasis can be life threatening in small children and ivermectin is a safe and effective cure for infected children weighing less than 15 kg [26,29,35,36,55].

Ivermectin for myiasis

The administration of oral ivermectin for myiasis has proven to be effective as it prevents complications in surgery and reduces the difficulty of mechanical removal of the larvae [56]. Children are vulnerable to nasal [57], oral [57,58], ocular [59–61], and auricular myiasis [57,62]. Treatment of children with oral ivermectin (200–350 μg/kg) for myiasis is effective [30,59–61,63] but use in children weighing less than 15 kg has been extremely limited due to the current contraindication [38,39].

Onchocerciasis, onchocerciasis-associated epilepsy and Nodding Syndrome

While the prevalence of onchocerciasis microfilaridermia in children aged less than five years is expected to be low, these children can become infected in areas of high O. volvulus transmission and present disease manifestations, especially pruritus [64]. The presence of troublesome itching may produce general fatigue, insomnia, and distraction at school [65,66]. It is possible that itching could be exacerbated in O. volvulus infected children weighing less than 15 kg that were treated with ivermectin, however, no studies were identified that assessed ivermectin in this weight class and disease combination. Trials in O. volvulus infected children weighing less than 15 kg are recommended before large scale ivermectin MDA rollout in onchocerciasis endemic regions in this weight class. In addition, the relative risk of excess mortality associated with onchocerciasis is higher, for a given microfilarial load, for younger age groups [67]. Furthermore, there is a consistent association between onchocerciasis and the incidence of onchocerciasis-associated epilepsy and Nodding Syndrome when the infection is intense and occurs at a very young age [68–73]. Nodding Syndrome, a form of epilepsy, may be caused by an autoimmune reaction to O. volvulus infection [74] and afflicts children between three and 18 years old [75]. Onchocerciasis-endemic regions where ivermectin MDAs are routinely performed have reduced [76–79]. All of these observations suggest that inclusion of children weighing less than 15 kg in ivermectin MDA will benefit child health in onchocerciasis endemic areas.

Ivermectin use for malaria control

Ivermectin has been proposed as a novel malaria control tool due to its ability to kill Anopheles mosquitoes and ivermectin MDA can suppress Plasmodium transmission [80–82]. When using ivermectin MDA as a malaria control agent, coverage is the most critical component of efficacy [83]. The contraindication of ivermectin for children weighing less than 15 kg excludes roughly 20% of the population in malaria endemic areas, potentially inhibiting MDA efficacy. In Africa, children under five years old are frequently bitten by Anopheles as evidenced by high rates of new malaria infections in this population [82]. Untreated small children serve an important reservoir of Plasmodium and can facilitate onwards transmission to mosquitoes.

Clinical trials have evaluated the safety, and efficacy of ivermectin along with the antimalarial drugs artemether-lumefantrine [84] and dihydroartemisinin-piperaquine [85,86] in adults. However, safety data in children and infants are needed in order to expand administration of these combinations to younger age groups. Currently in the African Sahel, seasonal malaria chemoprophylaxis (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SP-AQ) is given annually to 10–15 million children less than five years old, as an effective tool to reduce clinical incidence of severe malaria. Combining ivermectin MDAs with SMC would simultaneously target the parasite and vector, likely further reducing malaria in young children [87]. Before ivermectin and SP-AQ can be co-administered, safety and efficacy studies should be performed. Finally, ivermectin has been shown to inhibit liver-stage development of Plasmodium berghei [88], but its prophylactic efficacy in humans is debatable. Field evidence of repeated ivermectin (150 μg/kg) MDAs demonstrated that ivermectin treatment reduced the likelihood of infection and number of P. falciparum clones per infection beyond predicted community-wide transmission benefit, suggestive of ivermectin liver-stage prophylactic effect [82]. However, a recent controlled human malaria infection trial with single dose ivermectin (400 μg/kg) in adults failed to prevent P. falciparum infection [89]. If ivermectin can indeed inhibit Plasmodium development in treated humans, then this makes the inclusion of children weighing less than 15 kg in ivermectin MDAs for malaria control even more critical as they suffer a higher burden of morbidity and mortality from malaria.

Pediatric ivermectin formulations and dosage

Oral Ivermectin is typically delivered as 3 mg or 6 mg tablets, and while the 3 mg tablet size is relatively small, 5.5 mm diameter for Stromectol (Merck & Co., Whitehouse Station, NJ, USA), it can be difficult for young children to swallow oral tablets. Since there is no pediatric ivermectin formulation available in France, the French Medicines Regulatory Agency recommends to crush a whole 3 mg tablet for children weighing 10–15 kg or half of a three mg tablet for children weighing less than 10 kg, mix thoroughly in 10 mL of water, and administer [43]. In the clinical setting, there was no evidence of children weighing less than 15 kg choking when swallowing crushed ivermectin (3 mg) mixed in liquid (n = 169) [9]. A recent study milled three mg tablets into smaller 0.5 mg minitablets to provide to children aged two to 12 years old, many of whom weighed less than 15 kg (n = 43) [33]. In Latin America, a liquid oral formulation has been manufactured and used in several trials for treatment of young children with head lice in Colombia [90–92], and specifically in infants weighing less than 15kg for strongyloidiasis in Venezuela [26] and myiasis in Peru [30]. A liquid oral, minitablet, oro-dispersible minitablet, or multiparticulate formulation for small children would be advantageous for use in clinical treatment and MDA settings. The considerations outlined in this manuscript underline the need for the development of an adapted pediatric formulation of ivermectin.

The ideal dose of ivermectin for different indications in small children is not known. Available data suggest that adult based dosing is not appropriate for children and that dose escalation efficacy trials in children weighing less than 15 kg are needed. Recent pharmacokinetic analyses indicate that ivermectin treated children aged less than 12 years reach half the peak concentration and total exposure of adults [93] and a dose increase for young children was suggested [94]. A multi-center analysis found that ivermectin was significantly more effective at treating scabies in children weighing less than 15 kg when the dose was more than 200 μg/kg compared to less than 200 μg/kg [9]. This suggests that the standard 200 μg/kg dose of ivermectin may not reach effective levels in small children for all NTDs. This review identified 939 children treated with 201–300 μg/kg, 17 children treated with 301–400 μg/kg, and four children treated with >400 μg/kg. This limited evidence suggests that ivermectin doses greater >200 μg/kg are potentially safe and well tolerated in children weighing less than 15 kg. One limitation of this review is that most of the evidence 92.6% (1,007/1,088) is derived from two studies, one MDA study in the Solomon Islands [34] and a case series from France [9]. A multi-country, randomized, double-blind, placebo-controlled, dose escalation (200, 400, 800 μg/kg) study, dubbed the Ivermectin Safety in Small Children (ISSC) trial (NCT04332068) is currently underway, which is designed to assess the safety, pharmacokinetics, and efficacy of oral ivermectin in scabies-infected children weighing less than 15 kg [95]. An additional concern to ivermectin dosing in children weighing less than 15 kg are potential drug-drug interactions with other drugs frequently used in MDA populations (e.g. antiretrovirals) that may alter safety or pharmacokinetics.

A call for clarity in data reporting

Age is not a limiting criterion listed on most ivermectin package inserts but weight <15 kg and/or height <90 cm when used in MDAs are directly contraindicated [38]. However, there is a common misconception reported in the literature that children aged less than five years should not be administered ivermectin. Not treating children under five years of age would further restrict ivermectin use, as these children frequently weigh 15 kg or more or are 90 cm or taller [6]. Reports of ivermectin use in case studies, series, or trials frequently group subjects by age rather than by weight, providing no conclusive evidence for ivermectin safety in children weighing less than 15 kg. Of the 97 possible reports identified in this review, only four stated the number of children weighing less than 15 kg that were administered oral ivermectin [9,10,34,95]. Here we call for greater clarity when reporting ivermectin use in children to include the weight of any child below 15 kg and reporting of any associated AEs to the individual-patient level. An IPD call for ivermectin safety in children weighing less than 15 kg has been organized by WWARN and data from future publications or clarifications to publications cited in S1 Table can be contributed by contacting the study authors.

Disclaimer

Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its publication. The opinions or assertions contained herein are the private views of the author, and are not to be construed as official, or as reflecting true views of the Department of the Army or the Department of Defense. The investigators have adhered to the policies for protection of human subjects as prescribed in AR 70–25.